Published: December 2012

Publications

Prescriber Update Quiz 2012

This article is more than five years old. Some content may no longer be current.

Prescriber Update 33(4): 40
December 2012

Have you read your copy of Prescriber Update in 2012?
Have you kept up to date with emerging safety signals?

Test your knowledge with the end of year Prescriber Update quiz.

Answers to the quiz are available at:
www.medsafe.govt.nz/profs/PUarticles/QuizAnswersDec2012.htm

  1.  Name three medicines that are currently on Medsafe’s M² logo scheme?
    1. ……………………………………………….
    2. ……………………………………………….
    3. ……………………………………………….
  2. PML is caused by which virus?
    1. CJ virus
    2. JC virus
    3. Richie Cunningham virus
    4. Creutzfeldt-Jakob virus
  3. What does RCVS stand for?
    1. Reversible cerebral vascular swelling
    2. Reversible cardiac vasoconstriction swelling
    3. Reversible cerebral vasoconstriction syndrome
    4. Recurrent cardiac vasoconstriction syndrome
  4. True or false: Donepezil is associated with an increased risk of serotonin syndrome.
  5. In Zealand, which class of non-tuberculosis antibiotics is most often implicated in liver injury?
    1. Macrolides
    2. Tetracyclines
    3. Quinolones
    4. β-lactam penicillins
  6. What are some risk factors for statin-induced myopathy?
    1. female gender, high body-mass index, hyperthyroidism
    2. male gender, low body-mass index, hyperthyroidism
    3. male gender, high body-mass index, hypothyroidism
    4. female gender, low body-mass index, hypothyroidism
  7. Which healthcare professionals reported the most adverse reactions in 2011?
    1. General Practitioners
    2. Hospital Doctors
    3. Nurses
    4. Pharmacists
  8. Butterbur has been associated with adverse effects of the:
    1. skin
    2. cardiovascular system
    3. liver
    4. kidneys
  9. Which of these statements about interferon use is false?
    1. Patients should be screened for psychiatric symptoms before treatment.
    2. Mood and suicidal ideation should be monitored closely during therapy.
    3. Medical advice should be sought if symptoms of depression occur during interferon treatment.
    4. None of the above.
  10. The maximum recommended intravenous dose of ondansetron is:
    1. 8mg
    2. 16mg
    3. 32mg
    4. 64mg
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /